ArticleThe Journal of clinical investigation2021

Targeting enhancer reprogramming to mitigate MEK inhibitor resistance in preclinical models of advanced ovarian cancer.

Shini Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.